Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
Durvalumab|Intrahepatic Cholangiocarcinoma|Gemcis
DRUG: Durvalumab|PROCEDURE: Surgery|DRUG: Gemcitabine|DRUG: Cisplatin
1-year relapse free survival rate, 1-year
2-year relapse free survival rate, 2-year|ORR, 1-year|DCR, 1-year|R0 resection rate, 1-year|30 day postoperative complication rate, 30 day|Occurrence of adverse reactions, 1-year|1-year OS, 1-year|2-year OS, 2-year
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC